[
  {
    "ts": null,
    "headline": "Putnam Large Cap Value Fund Q4 2024 Commentary",
    "summary": "While US stocks overall posted a gain in the fourth quarter, value stocks fared differently, posting a modest negative return for the period.",
    "url": "https://finnhub.io/api/news?id=aeb92e66edaac5fe4e65f5b4d5d2bdee7f7625e0a724ba5862044a3ef0a67248",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743119100,
      "headline": "Putnam Large Cap Value Fund Q4 2024 Commentary",
      "id": 133504300,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1369582427/image_1369582427.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "While US stocks overall posted a gain in the fourth quarter, value stocks fared differently, posting a modest negative return for the period.",
      "url": "https://finnhub.io/api/news?id=aeb92e66edaac5fe4e65f5b4d5d2bdee7f7625e0a724ba5862044a3ef0a67248"
    }
  },
  {
    "ts": null,
    "headline": "LENZ Therapeutics Stock Is Attractive Before PDUFA",
    "summary": "LENZ Therapeutics, Inc.'s LNZ100 eye drops show strong phase 3 results for presbyopia, outperforming competitors. Click here to find out why LENZ is a Buy.",
    "url": "https://finnhub.io/api/news?id=a71a3e6db52b3b8b82423d488f6ac48c25291e163394fb7456090f6c802269b7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743096791,
      "headline": "LENZ Therapeutics Stock Is Attractive Before PDUFA",
      "id": 133489945,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1743870805/image_1743870805.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "LENZ Therapeutics, Inc.'s LNZ100 eye drops show strong phase 3 results for presbyopia, outperforming competitors. Click here to find out why LENZ is a Buy.",
      "url": "https://finnhub.io/api/news?id=a71a3e6db52b3b8b82423d488f6ac48c25291e163394fb7456090f6c802269b7"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=3198680eec5f6f63f571848c4069343d92dd2feed2dd8ea5a63a3988603afc27",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743080416,
      "headline": "AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know",
      "id": 133481361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=3198680eec5f6f63f571848c4069343d92dd2feed2dd8ea5a63a3988603afc27"
    }
  },
  {
    "ts": null,
    "headline": "VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug",
    "summary": "Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.",
    "url": "https://finnhub.io/api/news?id=20216feaf8f84f97ca0430e38d06cbf894929f9ccb4967c83b027fb867f382eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743078660,
      "headline": "VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug",
      "id": 133471694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.",
      "url": "https://finnhub.io/api/news?id=20216feaf8f84f97ca0430e38d06cbf894929f9ccb4967c83b027fb867f382eb"
    }
  },
  {
    "ts": null,
    "headline": "CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...",
    "summary": "Despite a significant revenue drop, CollPlant Biotechnologies Ltd (CLGN) focuses on promising collaborations and innovative product developments to drive future growth.",
    "url": "https://finnhub.io/api/news?id=0afa4455cee5b7f02508c277804e43cf6f8e528bb2ca9af2f073a48f30a099fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743058919,
      "headline": "CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...",
      "id": 133468015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Despite a significant revenue drop, CollPlant Biotechnologies Ltd (CLGN) focuses on promising collaborations and innovative product developments to drive future growth.",
      "url": "https://finnhub.io/api/news?id=0afa4455cee5b7f02508c277804e43cf6f8e528bb2ca9af2f073a48f30a099fb"
    }
  }
]